Spondyloarthritis & psoriatic arthritis
Where We Live Matters: Varied Disease Burden and Treatment Patterns in Psoriatic Arthritis in the United States
Main finding · High comorbidity burdenResult — go to the resultAdjusted odds ratio 1.59 95% CI 0.98–2.59Authors' conclusion
PsA disease characteristics and care vary across the US, with higher-than-expected prednisone use and unequal provider care burden in some regions.
Study context
- Population
- Patients with PsA in the Rheumatology Informatics System for Effectiveness (RISE) registry, January 2020–March 2023
- Participants
- 32,732 patients
- Exposure
- Geographic regions of the US
- Outcome
- Regional distribution of HDA (RAPID3 >12), high comorbidity (RxRisk ≥90th percentile), high ADI (≥80), insurance coverage, prednisone ≥10 mg daily and disease-modifying antirheumatic drug (DMARD) therapies
Methodological detailsregistry-based (RISE), logistic regression
- Registry-based (RISE)
- Logistic regression
Main finding
High comorbidity burden
Adjusted odds ratio
1.59
95% CI 0.98–2.59
Midwestvs Northeast
aOR 1.59 (95% CI 0.98–2.59)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Prednisone with csDMARDs
BMI ≥25
- BMI ≥25 in the cohort
- 81.8%
- Mean BMI in the Midwest (highest)
- 32.4 ± SD 7.8
Uveitis
- Uveitis in the cohort
- 1.2%
Concentration of care across RISE practices
- Practices caring for half of all Medicaid patients
- 14 (7.1%)
- Practices caring for half of all high-deprivation patients
- 20 (10.1%)
Original publication
Where We Live Matters: Varied Disease Burden and Treatment Patterns in Psoriatic Arthritis in the United States. Arthritis Rheumatol. Published 28 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →